Spondylitis Association of America
    Search Our Site:       

















Efficacy in current practice of switching between anti-tumour necrosis factor-a agents in spondyloarthropathies

Posted on: 12/13/2010

The Tumor-Necrosis-Factor alpha (TNF-a) blockers are biologic medications that have shown great promise in treating ankylosing spondylitis. They have been shown to be highly effective in treating not only the arthritis of the joints but the spinal arthritis associated with ankylosing spondylitis and related diseases.

This study looked at the effectiveness of switching between TNF-a medications to see if one would work when another had not.

The authors conclude that, "In the event of failure or intolerance to anti-TNF-a in the treatment of [spondyloarthropathies], performing a first or second switch produces a satisfactory therapeutic response.

Click here to read the abstract >>>


Spondylitis Information Donate to SAA



STAY INFORMED!

Stay up-to-date on all the latest news and information regarding AS and related diseases with our news magazine, Spondylitis Plus. Your subscription comes free with SAA membership, so click here to join today!



        Bookmark and Share RSS Feed


About Us |  Join SAA |  Educational Materials |  Contact Us |  Privacy Statement |  Guidestar |  Good Operating Practices
© 2011 Spondylitis Association of America, All Rights Reserved